C92.22 Atypical chronic myeloid leukemia, BCR/ABL-negative, in relapse

Name of the Condition

• Atypical chronic myeloid leukemia, BCR/ABL-negative, in relapse

Summary

Atypical chronic myeloid leukemia (aCML) is a rare myeloproliferative neoplasm characterized by the overproduction of abnormal myeloid cells in the bone marrow. This subtype lacks the BCR/ABL fusion gene and exhibits distinct clinical and genetic features. The condition disrupts normal blood cell production, leading to anemia, thrombocytopenia, or leukocytosis, and may progress to acute leukemia. The "in relapse" designation indicates a return of disease activity after a period of remission, with detectable disease manifestations or laboratory abnormalities.

Causes

aCML arises from genetic mutations in hematopoietic stem cells, though the specific mutations differ from those in BCR/ABL-positive CML. Common alterations involve genes regulating cell growth and differentiation, such as SETBP1, ETNK1, or ASXL1. These mutations drive uncontrolled proliferation of myeloid cells and impair normal maturation, contributing to disease relapse when residual or dormant cells reactivate.

Risk Factors

• Age: Primarily affects older adults, with incidence increasing after age 60.
• Prior myelodysplastic syndromes or other myeloid neoplasms.
• Exposure to certain chemotherapy agents or radiation (less common).
• No strong association with inherited genetic predisposition.

Symptoms

• Fatigue or weakness due to anemia.
• Unexplained weight loss or fever.
• Easy bruising or bleeding from low platelet counts.
• Frequent infections due to neutropenia.
• Enlarged spleen (splenomegaly).

Diagnosis

Diagnosis requires a combination of clinical evaluation, laboratory tests, and bone marrow analysis. Peripheral blood counts typically show leukocytosis with dysplastic features, anemia, or thrombocytopenia. Bone marrow biopsy reveals hypercellularity with abnormal myeloid proliferation and dysplasia. Cytogenetic testing confirms the absence of the BCR/ABL fusion gene, and molecular testing identifies mutations associated with aCML. Relapse is confirmed by recurrence of these abnormalities after prior remission.

Treatment Options

Treatment focuses on managing disease activity and symptoms. Options may include hypomethylating agents, chemotherapy, or targeted therapies. Allogeneic stem cell transplantation may be considered for eligible patients. Supportive care addresses cytopenias and infection risk. Treatment plans are tailored to the patient’s overall health and relapse severity.

Prognosis and Follow-Up

Prognosis varies based on disease characteristics and response to therapy. Relapse indicates a more aggressive course, with potential progression to acute leukemia. Regular monitoring includes blood counts, bone marrow assessments, and molecular testing to detect recurrence early. Follow-up care aims to manage symptoms and adjust treatment as needed.

Complications

• Progression to acute myeloid leukemia.
• Severe anemia, thrombocytopenia, or neutropenia.
• Increased infection risk.
• Organ dysfunction from leukemic infiltration.

Lifestyle & Prevention

No specific lifestyle changes prevent relapse, but general health measures support overall well-being. This includes balanced nutrition, regular exercise (as tolerated), and avoiding infections. Patients should avoid known triggers like unnecessary radiation exposure.

When to Seek Professional Help

Seek care if symptoms worsen, such as increased fatigue, unexplained bleeding, or recurrent infections. Prompt evaluation is necessary for suspected relapse to initiate or adjust treatment.

Tips for Medical Coders

Code C92.22 is specific to atypical chronic myeloid leukemia, BCR/ABL-negative, in relapse. Documentation must confirm the diagnosis of aCML, BCR/ABL negativity, and relapse status. Clinical notes should specify disease activity, prior remission, and any relevant laboratory or imaging findings to support coding accuracy.